

MGC Pharmaceuticals Ltd

01:47 19 Nov 2018

MGC Pharmaceuticals signs partnership to launch international medicinal cannabis research hub

MGC Pharmaceuticals Ltd (ASX:MXC) has signed a binding partnership agreement with the Royal Melbourne Institute of Technology (RMIT) and The Hebrew University of Jerusalem (HUJ) to form a joint international medical research hub for medicinal cannabis innovation and technologies.

As an extension to MGC's existing collaboration with RMIT, the new research hub, to be known as CannaHub, is a collaborative centre between MGC, RMIT and HUJ and will be an international shared library of research, data and analytics on medicinal cannabis and its uses including future medical applications and treatments.

The agreement represents a landmark achievement for MGC. The formation of CannaHub is the first time RMIT or HUJ has partnered with a private company to form a research institute in this sector.

READ: MGC Pharmaceuticals rockets up 37% after reimbursement win for cannabis epilepsy therapeutic

CannaHub's research projects will initially focus on three key areas in the use of medicinal cannabis, being the treatment of cancer, the effectiveness of traditional and medicinal cannabis combination treatments and drug delivery systems with technological elements.

Importantly, the results from the research project is expected to strategically position MGC as a leader in the cancer research and technology-based drug delivery space, enabling the company to develop and leverage its commercial intellectual property (IP) for the production of new medicinal cannabis products, applications and technologies.

"Collaboration is going to be crucial for this industry to grow the correct way"

Listen to this session led by Dr Nitin Mantri of RMIT and Ron Lipsky of MGC Pharma on 'Cannabusiness and Academia: Building For The Next Generation'. <https://t.co/8A0GW4Lgli>

— MGC Pharmaceuticals (@MGC_Pharma) November 8, 2018

MGC co-founder and managing director Roby Zomer said: "We are very pleased to announce the completion of our formal collaboration and partnership agreement with RMIT and HUJ to launch CannaHub.

"CannaHub is designed to advance world leading research and push forward innovation within the medicinal cannabis pharmaceutical market.

"We look forward to working with the teams at RMIT and HUJ and delivering ground breaking results in the future."

Price: 0.022

Market Cap: \$36.1 m

1 Year Share Price Graph



Share Information

Code: MXC

Listing: ASX

52 week High Low
0.042 0.015

Sector: Cannabis

Website: www.mgcpharma.com.au

Company Synopsis:

MGC Pharmaceuticals Ltd (ASX:MXC) is a European based bio-pharma company developing and supplying affordable standardised phytocannabinoid derived medicines.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of MGC Pharmaceuticals Ltd named herein, including the promotion by the Company of MGC Pharmaceuticals Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).